Pressure control apparatus

Information

  • Patent Grant
  • 11534540
  • Patent Number
    11,534,540
  • Date Filed
    Wednesday, May 18, 2022
    2 years ago
  • Date Issued
    Tuesday, December 27, 2022
    a year ago
Abstract
Methods and apparatuses are disclosed for applying negative pressure to a wound site. In some embodiments, the apparatus comprises a source of negative pressure, a processing element, and a memory comprising instructions configured to, when executed on the processing element, cause the apparatus to attempt to generate, via the source of negative pressure, a desired negative pressure at the wound site. If the desired negative pressure has not been generated after a first predetermined period of time, the instructions cause the apparatus to: deactivate the source of negative pressure for a second predetermined period of time, and subsequently attempt to generate the desired negative pressure at the wound site.
Description
BACKGROUND OF THE DISCLOSURE
Field of the Disclosure

The present invention relates to a method and apparatus for applying a negative pressure. In particular, but not exclusively, the present invention relates to the application of a negative pressure to a wound site in the application of topical negative pressure at the wound site.


Background

There is much prior art available relating to the provision of apparatus and methods of use thereof for the application of topical negative pressure (TNP) therapy to wounds together with other therapeutic processes intended to enhance the effects of the TNP therapy. Examples of such prior art include those listed and briefly described below.


TNP therapy (sometimes referred to as Vacuum Assisted Closure or negative pressure wound therapy) assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow and granulation of tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.


In International patent application, WO 2004/037334, which is incorporated herein by reference, apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, the application describes the treatment of a wound by the application of TNP therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.


In International patent application, WO 2005/04670, which is incorporated herein by reference, apparatus, a wound dressing and a method for cleansing a wound using aspiration, irrigation and cleansing are described. Again, in very general terms, the invention described in this document utilises similar apparatus to that in WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound.


However, the above described apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus used is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.


Some patients having relatively less severe wounds which do not require continuous hospitalisation, for example, but whom nevertheless would benefit from the prolonged application of TNP therapy, could be treated at home or at work subject to the availability of an easily portable and maintainable TNP therapy apparatus. To this end GB-A-2 307 180 describes a portable TNP therapy unit which may be carried by a patient and clipped to belt or harness. A negative pressure can thus be applied at a wound site.


However, this portable apparatus is still relatively bulky, and may require monitoring of the patient by a trained caregiver. Furthermore, such portable therapy units commonly have reduced capacity to deal with fluid flow rates into a wound cavity caused by leaks. This leads to a greater number of alarms being raised due to an inability to maintain the desired negative pressure at the wound site in the presence of leaks.


Another problem associated with portable apparatus is that on occasion an onboard power source such as a battery pack is used rather than a continuous connection to a power source such as a mains power source. It will be appreciated that such a battery pack has only a limited power resource and therefore TNP therapy can on occasion be halted prior to a desired moment in time because of power failure.


Another problem associated with therapy units which can be utilised by a patient alone without the need for skilled technical assistants is that from time to time warning lights or warning alarms may be initiated when a desired therapy can not be maintained or initiated. This can be distressing for a patient who may not understand the meaning of the cues.


A still further problem associated with the apparatus used to provide TNP therapy is that from time to time a motor associated with a pump which generates a negative pressure will start up or stop. The change in volume coming from the therapy unit can be a cause of concern to a patient.


SUMMARY OF SOME EXEMPLIFYING EMBODIMENTS

It is an aim of certain embodiments of the present invention to at least partly mitigate one or more of the above-mentioned problems.


It is an aim of certain embodiments of the present invention to provide a method for controlling the provision of a desired negative pressure at a wound site to aid in wound closure and healing.


It is an aim of certain embodiments of the present invention to provide a pressure control apparatus that avoids the generation of unnecessary alarms in the presence of transient leaks.


It is an aim of certain embodiments of the present invention to provide a pressure control apparatus that helps extend battery power lifetime.


It is an aim of certain embodiments of the present invention to provide a pressure control apparatus that reduces a number of pump motor start-up or power down operations.


According to a first aspect of the present invention there is provided apparatus for dressing a wound for the application of topical negative pressure at a wound site, comprising:

    • a source of negative pressure;
    • a processing element;
    • a memory comprising instructions configured to, when executed on the processor, cause the apparatus to perform the steps of:
    • via the source of negative pressure, attempting to generate a desired negative pressure at the wound site;
    • if the desired negative pressure has not been generated after a first predetermined period of time, deactivating the source of negative pressure for a second predetermined period of time; and
    • subsequently attempting to generate the desired negative pressure at the wound site.


According to a second aspect of the present invention there is provided a method of applying topical negative pressure (TNP) at a wound site, comprising the steps of:

    • via a source of negative pressure, attempting to generate a desired negative pressure at the wound site;
    • if the desired negative pressure has not been generated after a first predetermined period of time, deactivating the source of negative pressure for a second predetermined period of time; and
    • subsequently attempting to generate the desired negative pressure at the wound site.


According to a third aspect of the present invention there is provided an apparatus for applying negative pressure to a wound, comprising:

    • a source of negative pressure coupled to a dressing; and
    • a controller configured to:
      • activate the source of negative pressure to generate a first desired negative pressure under the dressing;
      • if, upon an expiration of a first time interval, a negative pressure under the dressing has not reached the first desired negative pressure, deactivate the source of negative pressure for a second time interval; and
      • upon expiration of the second time interval, activate the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the controller is further configured to: deactivate the source of negative pressure when the first desired negative pressure has not been generated under the dressing after activating the source of negative pressure for a first number of times exceeding a first threshold.


In some embodiments, the controller is further configured to: when the first number of times exceeds the first threshold, deactivate the source of negative pressure for a third time interval.


In some embodiments, the apparatus further comprises: a switch configured to signal to the controller to activate or deactivate the source of negative pressure; and the controller is further configured to, upon expiration of the third time interval or upon receiving a signal to activate the source of negative pressure from the switch, activate the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the apparatus further comprises: an indicator, wherein the controller is further configured to activate the indicator when the first number of times exceeds the first threshold.


In some embodiments, the controller is further configured to: deactivate the indicator upon expiration of the third time interval or receiving a signal to activate the source of negative pressure from the switch.


In some embodiments, the indicator indicates a leak in the seal.


In some embodiments, the controller is further configured to:

    • when the negative pressure under the dressing has reached the first desired negative pressure, deactivate the source of negative pressure and monitor negative pressure under the dressing; and
    • if the negative pressure under the dressing drops below a negative pressure threshold, activate the source of negative pressure to generate a second desired negative pressure under the dressing.


In some embodiments, the first and second desired negative pressure are the same.


In some embodiments, the second desired negative pressure is less than the first desired negative pressure.


In some embodiments, the controller is further configured: to deactivate the source of negative pressure if the negative pressure under the dressing has reached the second desired negative pressure or if the negative pressure under the dressing has not reached the second desired negative pressure upon expiration of a fourth time interval.


In some embodiments, if the negative pressure under the dressing has not reached the second desired negative pressure upon expiration of the fourth time interval, the controller is further configured to, upon expiration of the second time interval, activate the source of the negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the controller is further configured to: activate the source of the negative pressure to generate the first desired negative pressure under the dressing if the controller has activated the source of negative pressure to reach the second desired negative pressure for a second number of times less than a second threshold.


In some embodiments, the controller is further configured to:

    • deactivate the source of negative pressure if the controller has activated the source of negative pressure to reach the second desired negative pressure for the second number of times exceeding the second threshold; and
    • upon expiration of the third time interval or upon receiving the signal from the switch to activate the source of negative pressure, activate the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the controller is further configured to:

    • monitor a duty cycle of the source of negative pressure; and
    • deactivate the source of negative pressure if the duty cycle exceeds a first duty cycle threshold without the negative pressure reaching the first or second desired negative pressure under the dressing.


In some embodiments, the duty cycle comprises an amount, proportion, or percentage of time the source of negative pressure is active over a period of time.


In some embodiments, the controller is further configured to: calculate a number of duty cycles that exceed the first duty cycle threshold and deactivate the source of negative pressure when the number of duty cycles that exceed the first duty cycle threshold exceeds a second duty cycle threshold.


In some embodiments, the controller is further configured to calculate a number of consecutive duty cycles that exceed the first duty cycle threshold.


In some embodiments, the second duty cycle threshold comprises 30 minutes.


In some embodiments, the controller is further configured: to upon expiration of the third time interval or upon receiving the signal from the switch to active the source of negative pressure, activate the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the source of negative pressure comprises a pump.


In some embodiments, the apparatus further comprises: a pressure sensor configured to sense pressure under the dressing and to communicate the sensed pressure to the controller.


In some embodiments, the apparatus further comprises: a one-way valve coupled between an inlet and the source of negative pressure, wherein the inlet is in fluid communication with the dressing.


In some embodiments, the source of negative pressure comprises: a valve configured to connect the port to an external source of negative pressure.


In some embodiments, the controller is further configured to: activate or deactivate the source of negative pressure by operating the valve.


According to a fourth aspect of the present invention there is provided a method of applying negative pressure to a wound, comprising:

    • positioning a dressing over the wound to create a substantially fluid impermeable seal over the wound;
    • coupling a source of negative pressure to the dressing;
    • activating the source of negative pressure to generate a first desired negative pressure under the dressing;
    • if, upon an expiration of a first time interval, a negative pressure under the dressing has not reached the first desired negative pressure, deactivating the source of negative pressure for a second time interval; and
    • upon expiration of the second time interval, activating the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the method further comprises: deactivating the source of negative pressure when the first desired negative pressure has not been generated under the dressing after activating the source of negative pressure for a first number of times exceeding a first threshold.


In some embodiments, the method further comprises: deactivating the source of negative pressure for a third time interval when the first number of times exceeds the first threshold.


In some embodiments, the method further comprises: activating the source of negative pressure to generate the first desired negative pressure under the dressing upon expiration of the third time interval or upon receiving a signal to activate the source of negative pressure from a switch.


In some embodiments, the method further comprises: indicating to a user when the first number of times exceeds the first threshold.


In some embodiments, the method further comprises: stopping the indication upon expiration of the third time interval or receiving a signal to activate the source of negative pressure from the switch.


In some embodiments, the indicating indicates a leak in the seal.


In some embodiments, the method further comprises:

    • when the negative pressure under the dressing has reached the first desired negative pressure, deactivating the source of negative pressure and monitoring negative pressure under the dressing; and
    • if the negative pressure under the dressing drops below a negative pressure threshold, activating the source of negative pressure to generate a second desired negative pressure under the dressing.


In some embodiments, the first and second desired negative pressure are the same.


In some embodiments, the second desired negative pressure is less than the first desired negative pressure.


In some embodiments, the method further comprises: deactivating the source of negative pressure if the negative pressure under the dressing has reached the second desired negative pressure or if the negative pressure under the dressing has not reached the second desired negative pressure upon expiration of a fourth time interval.


In some embodiments, the method further comprises: if the negative pressure under the dressing has not reached the second desired negative pressure upon expiration of the fourth time interval, activating the source of the negative pressure to generate the first desired negative pressure under the dressing upon expiration of the second time interval.


In some embodiments, the method further comprises: activating the source of the negative pressure to generate the first desired negative pressure under the dressing if the source of negative pressure has been activated to reach the second desired negative pressure for a second number of times less than a second threshold.


In some embodiments, the method further comprises:

    • deactivating the source of negative pressure if the source of negative pressure has been activated to reach the second desired negative pressure for the second number of times exceeding the second threshold; and
    • upon expiration of the third time interval or upon receiving the signal from the switch to activate the source of negative pressure, activating the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the method further comprises:

    • monitoring a duty cycle of the source of negative pressure; and
    • deactivating the source of negative pressure if the duty cycle exceeds a first duty cycle threshold without the negative pressure reaching the first or second desired negative pressure under the dressing.


In some embodiments, the duty cycle comprises an amount, proportion, or percentage of time the source of negative pressure is active over a period of time.


In some embodiments, the method further comprises: calculating a number of duty cycles that exceed the first duty cycle threshold and deactivating the source of negative pressure when the number of duty cycles that exceed the first duty cycle threshold exceeds a second duty cycle threshold.


In some embodiments, the method further comprises: calculating a number of consecutive duty cycles that exceed the first duty cycle threshold.


In some embodiments, the second duty cycle threshold comprises 30 minutes.


In some embodiments, the method further comprises: upon expiration of the third time interval or upon receiving the signal from the switch to active the source of negative pressure, activating the source of negative pressure to generate the first desired negative pressure under the dressing.


In some embodiments, the source of negative pressure comprises a pump.


In some embodiments, the method further comprises sensing pressure under the dressing.


In some embodiments, the method further comprises: activating or deactivating the source of negative pressure by operating a valve.


Certain embodiments of the present invention provide the advantage that the raising of alarms due to transient leaks into a wound chamber can be avoided, while also reducing the potential for drawing contaminants into a wound site through a leak into the wound chamber.


Certain embodiments of the present invention provide the advantage of extending the useful life of a battery powered source of negative pressure used to provide a desired negative pressure to a wound site.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present invention will now be described hereinafter, by way of example only, with reference to the accompanying drawings in which:



FIG. 1 illustrates an arrangement for applying negative pressure wound therapy to a wound site;



FIG. 2 illustrates a schematic representation of a pressure control apparatus;



FIG. 3 illustrates a schematic representation of a further pressure control apparatus;



FIG. 4 illustrates a state diagram of a controller; and



FIG. 5 illustrates a controller.





In the drawings like reference numerals refer to like parts.


DETAILED DESCRIPTION OF SOME EXEMPLIFYING EMBODIMENTS


FIG. 1 illustrates an arrangement for applying negative pressure wound therapy to a wound site 10. A packing material 12 is placed within a wound cavity, and then a drape 14 sealed to the surface of the skin around the wound site 10 forming a fluid tight seal around the perimeter of a wound chamber. A source of negative pressure, such as a pressure control apparatus 100 is coupled to the wound cavity via a tube 16. A fluid collection canister (not shown) may be coupled between the pressure control apparatus 100 and the wound chamber to collect any wound exudate drawn from the wound site 10. The use of the packing material 12 is optional, and it may be omitted in certain arrangements as appropriate.


Alternatively, a self contained wound dressing may be used in place of the drape, such a wound dressing absorbs wound exudate within the layers of the dressing removing the need for a separate fluid collection canister.


Further details regarding wound dressings that may be used in combination with the embodiments described herein are found in U.S. application Ser. No. 13/092,042, filed Apr. 21, 2011, the entirety of which is hereby incorporated by reference.


It is envisaged that the negative pressure range for the apparatus in certain embodiments of the present invention may be between about −50 mmHg and −200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, −200 mmHg would be about 560 mmHg in practical terms). Aptly, the pressure range may be between about −75 mmHg and −150 mmHg. Alternatively a pressure range of upto −75 mmHg, upto −80 mmHg or over −80 mmHg can be used. Also aptly a pressure range of below −75 mmHg could be used. Alternatively a pressure range of over −100 mmHg could be used or over −150 mmHg.



FIG. 2 illustrates a schematic representation of a pressure control apparatus 100 according to embodiments of the invention that can be used to apply negative pressure to a wound site 10. The pressure control apparatus includes an inlet 102 coupled to a pressure sensor 116, and also to an inlet of a pump 106 via a one-way check valve 104. The pump is operated by an electric motor 108, which draws power from a battery 114. A controller 112 is coupled to the pressure sensor 116 and provides control signals for controlling the operation of the electric motor 108. Indicators 110 are coupled to the controller 112 to allow audio and/or visual feedback of status signals to a user. An outlet of the pump 106 is coupled to an outlet 118 of the pressure control apparatus. A user can utilise a power button 120 to initiate or terminate operation.


The pump 106 shown is a diaphragm pump which may be highly efficient and capable of providing the required negative pressure. It will be appreciated that other types of pump such as peristaltic pumps, or the like can be used. In some arrangements, the one-way check valve 104 may form part of the pump 106, and may not exist as a separate element of the apparatus.


While the apparatus has been described as being battery powered, it will be understood that the apparatus could alternatively draw electrical power from a mains power supply and the battery power cell removed. In some arrangements, the apparatus may be capable of being powered from either a mains power supply or a rechargeable battery that may be recharged from the mains power supply.


In operation, the inlet 102 is coupled to a wound chamber formed over a wound site 10, for example via the length of tube 16. The electric motor 108 drives the pump 106 under the control of the controller 112 to provide a negative pressure at the inlet 102. The negative pressure can then be communicated to the wound chamber in order to provide a desired negative pressure at the wound site. The check valve 104 maintains the level of negative pressure at the inlet 102 when the pump 106 is not active and helps avoid leaks.


Upon initially connecting the pressure control apparatus 100 to the wound chamber, the pressure at the wound site will be equal to atmospheric pressure, and an initial pump-down must be performed to establish the desired negative pressure at the wound site. This may require the pump 106 to be operated for an extended period of time until the desired negative pressure is achieved.


The pressure at the inlet 102 is indicative of the pressure experienced at the wound site, and this pressure is measured by the pressure sensor 116. The controller 112 receives the pressure value measured at the pressure sensor 116, and once the measured pressure reaches the desired negative pressure, the controller deactivates the pump 106. The controller 112 then continues to monitor the pressure at the pressure sensor.


If during the initial pump-down phase, the controller 112 determines that the desired negative pressure has not been achieved within a certain time (for example 10 minutes or 20 minutes or 30 minutes or 40 minutes or the like), then leaks may be present into the wound chamber, and this condition is signalled via the indicators 110 to show that the wound chamber has not been correctly sealed, or some other error or fault is present.


Once the desired negative pressure has been established, the controller 112 monitors the pressure at the inlet of the pressure control apparatus. From time to time, leaks of fluid may occur into the wound chamber, reducing the level of negative pressure experienced at the wound site, or in other words increasing the absolute pressure at the wound site. The pressure value measured at the pressure sensor 116 and provided to the controller 112 will therefore increase as fluid leaks into the wound chamber. When the measured negative pressure value drops below a certain defined pressure level, the controller 112 will reactivate the pump 106 in order to re-establish the desired negative pressure at the wound site. The desired negative pressure and the defined pressure level at which the controller reactivates the pump provide hysteresis limits between which the pressure should be maintained to apply topical negative pressure to the wound site.


However, if a leak forms that allows fluid, for example air, to leak into the wound chamber with a flow rate greater than the maximum pump capacity 106, it will not be possible for the pressure control apparatus 100 to maintain the desired negative pressure at the wound site. If the pressure control apparatus 100 continued to attempt to re-establish the desired negative pressure in the presence of such a leak, the battery power cell 114 would become depleted. Furthermore, continued operation of the pump in the presence of a large leak can draw contaminants into the wound site, and lead to excessive drying of the wound site which is undesirable. Therefore, the controller 112 is configured to deactivate the pump 106 if the desired negative pressure is not re-established after operation of the pump 106 for a predetermined period of time. For example sometime between around 30 minutes and 4 hours.


The formation of leaks into the wound chamber may occur due to a range of factors. One common cause of such leaks is movement of a patient being treated with the pressure control apparatus 100. For example, a leak may form when a patient moves from a lying to a sitting position, or during the normal range of movement when walking. Such leaks may be transient, and have been found to regularly reseal as the patient continues to move or returns to their previous position. Thus, there is a risk that the pump 106 may be deactivated due to the detection of a leak that subsequently reseals. However, once the leak reseals, operation of the pressure control apparatus would be able to re-establish the desired negative pressure within the wound chamber.


According to embodiments of the invention, the controller 112 is configured to deactivate the pump 106 after the pump has operated for a certain period of time without the desired level of negative pressure being reached in the wound chamber. That is a timeout event occurs. The controller then waits for a further period of time before a retry attempt is made to re-establish the desired negative pressure at the wound site using the pump 106. If the leak has resealed while the pump has been temporarily deactivated, the retry attempt to re-establish the desired negative pressure will be successful, and operation of the pressure control apparatus 100 can continue as normal. However, if the leak is still present a further timeout event will occur and the pump will be deactivated for the further period of time.


This cycle of deactivating the pump 106 and then attempting to re-establish the desired negative pressure may be repeated a number of times in order to provide an opportunity for any leaks to reseal. However, once a timeout event occurs the negative pressure at the wound site will start to degrade, and therefore there will be a break in the negative pressure wound therapy applied to the wound site. While a short break in therapy may not be a concern, an extended period in which the negative pressure is not applied should preferably be avoided. Furthermore, if a leak path into the wound chamber exists for an extended period of time, the potential for contaminants reaching the wound site increases. Thus, if a number, N, of unsuccessful attempts are made to re-establish the desired negative pressure it can be assumed that the leak is permanent, and not transient, and the controller 112 disables operation of the pressure control apparatus 100 and provides a signal via an audio and/or visual cue to a user that attention is required. This allows a patient or caregiver to arrange for any dressings or drapes to be changed to thereby reform the wound chamber and allow the negative pressure wound therapy to be continued. Aptly N is an integer between 1 and 5 inclusive.


Alternatively, the pump 106 and motor 108 may be omitted, and the negative pressure may be provided via an external source of negative pressure, such as by connection to a vacuum line or vacuum reservoir. FIG. 3 provides a schematic representation of a further pressure control apparatus 200 for use with an external source of negative pressure, and which can be used to provide negative pressure to a wound site 10. Pressure control apparatus 200 includes a controllable valve 202 coupled between an inlet 102 and an outlet 118. The outlet 118 is coupled to the external source of negative pressure. Controller 212 provides control signals to the valve 202 to control the coupling of the external source of negative pressure to the inlet 102, and thereby to the wound chamber. The pressure at the inlet 102 is monitored by a pressure sensor 116, coupled to the inlet, and this monitored pressure is supplied to the controller 212.


The operation of the pressure control apparatus 200 of FIG. 3 is similar to that of the pressure control apparatus 100, except that pressure is controlled by operating the valve 202 to couple the wound chamber to the external source of negative pressure. Controller 112 is able to control the level of negative pressure at the inlet 102 by controlling the valve 202. By monitoring the pressure at the inlet via the pressure sensor 116, the controller 212 can control the valve to provide the desired negative pressure at the wound site.


Unlike the pressure control apparatus of FIG. 2, an extended attempt to provide the desired negative pressure in the presence of a leak will not lead to depletion of a battery power cell. However, longterm it is still undesirable to continue to apply a negative pressure in the presence of a leak due to the possibility of drawing contaminants into the wound chamber, and of drying out the wound site due to the flow of air through the chamber. Thus, the controller 212 of FIG. 3 implements the same control flow as described above with respect to the pressure control apparatus 100. That is, controller 212 is configured to de-couple the inlet 102 from the external source of negative pressure by closing the valve if the desired negative pressure is not established at the wound site within a predetermined period of time. A number of attempts may then be made to re-establish the desired negative pressure in order to provide the opportunity for transient leaks into the wound chamber to reseal.


Thus, the pressure control apparatus of FIGS. 2 and 3 are able to control the application of negative pressure to a wound site, and advantageously reduce the number of alarms due to transient leaks of fluid into the wound chamber. When a leak forms that allows air into the wound chamber at a flow rate above a certain level, the pressure control apparatus is configured to disable the provision of negative pressure to the wound chamber for a predetermined period of time, providing an opportunity for the leak to reseal. Then, if the leak is transient and reseals, the desired negative pressure may then be re-established at a subsequent attempt. This avoids the need to indicate an alarm condition for transient leaks, and also avoids the problem of drawing contaminants and excessive amounts of air into the wound chamber. This also avoids a pump motor being repeatedly energised and de-energised which avoids concerning noise level changes and helps improve pump motor longevity.


Controller 112, 212 may be implemented as a microcontroller, or an application specific integrated circuit, or the like, and may execute instructions to provide the above described control functions. For example, a suitable microcontroller would be one from the STM8L MCU family from ST Microelectronics, for example ST Microelectronics STM8L151G4U6, or one from the MC9S08QE4/8 series from Freescale, such as the Freescale MC9S08QE4CWJ.


The operation of the controller 112 may be described as a finite state machine. The operation of the controller is described below with reference to FIG. 4 which shows a state diagram 300 describing the operation of the controller 112 for the pressure control apparatus shown in FIG. 1.



FIG. 5 illustrates one embodiment of controller 112. The controller comprises a memory 502, which may hold program code for implementing the control functions. The memory is coupled to a microcontroller 504 able to execute the instructions. The microcontroller is coupled to inputs 506 and outputs 508 through which the microcontroller is able to monitor the operation of the system and provide control signals to other parts of the pressure control apparatus.


Referring again to FIG. 4 upon activation 310 of the pressure control apparatus 100 which may occur when an activation strip is pulled for the first time or a user button is pressed or the like, the controller 112 performs a power-on self test (POST) 302 to ensure that the pressure control apparatus is operating correctly. If the power-on self test is failed the pressure control apparatus should not be used. Therefore, after a failed POST, the controller transitions to a non-recoverable error state 304 and the error is signalled to the user via indicators 110. If the POST is passed, the controller 112 transitions to an operational state 308 via a standby state, and performs an initial pump down 312 when a user indicates via a button, in which the pump 106 is operated until a desired negative pressure is established in the wound chamber. Alternatively, the controller may wait on a user input before performing the initial pump-down in state 312.


Once the desired negative pressure has been successfully established, the controller transitions to the monitor pressure state 316. However, if after a predetermined period of time the desired pressure has not been established and the initial pump down state 312 is unable to establish the desired negative pressure (indicative of a leak), a timeout occurs. On the first timeout, the controller will transition to a wait state 314, in which the controller waits for a period of time before transitioning back to the initial pump down state 312. Further timeouts may occur from the initial pump-down state 312, and the controller maintains a count of the number of retry attempts made. Once the desired negative pressure has been established, the number of retry attempts may be reset.


If a timeout occurs and the number of retry cycles is greater than a predefined maximum number of retry attempts allowed, the controller transitions to a paused state 306. While in the paused state 306 the controller will transition from the paused state 306 to the initial pump down state 312 in response to a user input, or after a maximum pause time.


In the monitor pressure state 316, the controller monitors the pressure measured at the pressure sensor 116 and, if the pressure drops out of the desired pressure range, the controller transitions to a maintenance pump-down state 318. In the maintenance pump-down state 318, the suction pump is activated either for a predetermined period of time, for example between around 10 and 60 seconds, or until the desired negative pressure is re-established in the wound chamber, whichever occurs sooner.


It is noted that some hysteresis is built into the desired pressure range, such that the pressure value, a minimum desired negative pressure, that triggers a transition from the monitor pressure state 316 to the maintenance pump-down state 318 is lower than the desired negative pressure established in the wound chamber by operation of the pump during the maintenance pump-down state 318. For example, taking the operating pressure ranges discussed above, the desired negative pressure may be −150 mmHg and the minimum desired negative pressure may be −75 mmHg. Alternatively, the controller may act to maintain the pressure within a certain percentage range of the desired negative pressure, for example a 5% hysteresis may be used.


If the desired negative pressure is reached before the suction pump has been operating for the predetermined period of time, the controller transitions back to the monitor pressure state 316.


However, if the pump operates for the predetermined period of time without the desired negative pressure being re-established in the wound chamber, normally due to a leak into the wound chamber, the pressure control apparatus will signal the presence of a leak. If the pressure is within the hysteresis limits, i.e. between the minimum desired negative pressure and the desired negative pressure, this signifies the presence of a high leak, having a flow rate similar to the capacity of the pump. In this situation, the pump continues to operate until the desired negative pressure is re-established, or until the pressure at the wound site is no longer held within the hysteresis limits.


If in the presence of a large leak, the desired negative pressure is restored before a maximum maintenance time is reached, the controller will transition back to the monitor pressure state 316, but will signal the presence of a leak. However, if the suction pump is operated for more than the maximum maintenance time to restore the desired negative pressure, the controller will transition to the paused state 306, while signalling the presence of a leak.


If during the maintenance pump-down state 318, the pressure in the wound chamber is not maintained within the hysteresis limits, a catastrophic leak has occurred, and the controller transitions to the wait state 314.


In some embodiments, if after a predetermined period of time, the desired pressure has not been established and the maintenance pump down state 318 is unable to establish the desired negative pressure before the maximum maintenance time is reached, a timeout occurs. On the first timeout, the controller will transition to the wait state 314, in which the controller waits for a period of time before transitioning back to the initial pump down state 312. Further timeouts may occur from the maintenance pump-down state 318, and the controller maintains a count of the number of retry attempts made. Once the desired negative pressure has been established in the maintenance pump down state 318, the number of retry attempts may be reset. If a timeout occurs and the number of retry attempts is greater than a predefined maximum number of retry attempts allowed, the controller transitions to the paused state 306, as described above.


Thus, if the leak is such that it is over a prescribed limit and the pump duty cycle (DC) as defined, in some embodiments, as pump on time divided by pump off time is over a predetermined limit then the pump shall continue to operate within the hysteresis limits for a particular time duration. For example, around 30 minutes as shown in FIG. 4. Thus, in the monitor pressure loop if the duty cycle is less than a predetermined limit then all is okay. If the duty cycle is greater than a particular limit but less than a time out time the pump continues to run for up to 30 minutes. If DC is greater than time out then a paused state 306 is entered.


At any time while in the operational state 308, the controller may be placed in the pause state 306 in response to a user input. Once the battery voltage reaches a low voltage cut off level or the lifetime of the pressure control apparatus has been reached, the controller de-activates the pressure control apparatus and an End of Life state is reached.


The controller 212 described with respect of the pressure control apparatus 200 of FIG. 3 operates in a similar manner as described above except that the initial pump-down and maintenance pump-down states are replaced with valve activation states in which the inlet 102 is coupled to the external source of negative pressure connected to the outlet 118 via controllable valve element 202.


Alternatively, the POST state 302 may be omitted.


The pressure control apparatus may be configured to be re-useable and be provided with a switch to allow the apparatus to be turned on and off as required. Such a re-usable apparatus may include rechargeable power cells, and may provide a low power indication in order to allow the power cells to be replaced/recharged.


In a disposable single use pressure control apparatus, activation may be provided by pulling an activation strip and it may not be possible to deactivate the apparatus once activated until the apparatus is to be discarded.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.


Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

Claims
  • 1. A negative pressure wound therapy device comprising: a negative pressure source configured to provide negative pressure via a fluid flow path to a wound covered by a wound dressing;at least one visual indicator;a controller; anda memory storing instructions that, when executed by the controller, cause the controller to: activate the negative pressure source to attempt to establish a desired level of negative pressure in the fluid flow path;provide a first indication using the at least one visual indicator to indicate a leak has been detected in the fluid flow path;determine that the leak has not been remedied;responsive to determining that the leak has not been remedied, deactivate the negative pressure source for a duration of time; andresponsive to expiration of the duration of time, activate the negative pressure source to attempt to establish the desired level of negative pressure in the fluid flow path.
  • 2. The negative pressure wound therapy device of claim 1, wherein the instructions, when executed by the controller, further cause the controller to: responsive to determining that the leak has not been remedied, provide a second indication using the at least one visual indicator, the second indication being different than the first indication.
  • 3. The negative pressure wound therapy device of claim 1, wherein the instructions, when executed by the controller, further cause the controller to: become active responsive to detection of an activation event;subsequent to becoming active and responsive to a first user input received via a button, activate the negative pressure source to supply negative pressure under the wound dressing; andbecome inactive responsive to determining that a lifetime threshold has been reached.
  • 4. The negative pressure wound therapy device of claim 3, wherein the instructions, when executed by the controller, further cause the controller to: responsive to a second user input received via the button, deactivate the negative pressure source.
  • 5. The negative pressure wound therapy device of claim 4, wherein the instructions, when executed by the controller, further cause the controller to: responsive to deactivating the negative pressure source, provide a second indication using the at least one visual indicator, the second indication being different than the first indication.
  • 6. The negative pressure wound therapy device of claim 1, wherein the at least one visual indicator comprises a first indicator configured to indicate the leak and a second indicator configured to indicate that a remaining capacity of a power source satisfies a low capacity threshold, and wherein the instructions, when executed by the controller, further cause the controller to: provide a second indication using the second indicator to indicate that the remaining capacity satisfies the low capacity threshold.
  • 7. The negative pressure wound therapy device of claim 1, wherein the instructions, when executed by the controller, further cause the controller to: become active responsive to detection of an activation event;perform a self-test subsequent to becoming active; andresponsive to determining that the self-test has been completed successfully, await user input to activate the negative pressure source.
  • 8. The negative pressure wound therapy device of claim 7, wherein the instructions, when executed by the controller, further cause the controller to: determine that the self-test has failed; andresponsive to determining that the self-test has failed, transition to an error state and provide a second indication via the at least one visual indicator, the second indication being different than the first indication.
  • 9. The negative pressure wound therapy device of claim 1, wherein the at least one visual indicator comprises three visual indicators.
  • 10. A kit comprising the negative pressure wound therapy device of claim 1 and the wound dressing, wherein the wound dressing comprises an absorbent wound dressing.
  • 11. A kit comprising the negative pressure wound therapy device of claim 1 and a canister configured to store exudate aspirated from the wound.
  • 12. A method of operating a negative pressure wound therapy device comprising a controller, a negative pressure source, and at least one visual indicator, the method comprising: activating the negative pressure source to attempt to establish a desired level of negative pressure in a fluid flow path connecting the negative pressure source to a wound covered by a wound dressing;providing a first indication using the at least one visual indicator to indicate a leak has been detected in the fluid flow path;determining that the leak has not been remedied;in response to determining that the leak has not been remedied, deactivating the negative pressure source for a duration of time; andresponsive to expiration of the duration of time, activating the negative pressure source to attempt to establish the desired level of negative pressure in the fluid flow path,wherein the method is performed by the controller.
  • 13. The method of claim 12, further comprising: responsive to determining that the leak has not been remedied, providing a second indication using the at least one visual indicator, the second indication being different than the first indication.
  • 14. The method of claim 12, further comprising: becoming active responsive to detection of an activation event;subsequent to becoming active and responsive to a first user input received via a button of the negative pressure wound therapy device, activating the negative pressure source to supply negative pressure under the wound dressing; andbecoming inactive responsive to determining that a lifetime threshold has been reached.
  • 15. The method of claim 14, further comprising: responsive to a second user input received via the button, deactivating the negative pressure source.
  • 16. The method of claim 15, further comprising: responsive to deactivating the negative pressure source, providing a second indication using the at least one visual indicator, the second indication being different than the first indication.
  • 17. The method of claim 12, wherein the at least one visual indicator comprises a first indicator configured to indicate the leak and a second indicator configured to indicate that a remaining capacity of a power source satisfies a low capacity threshold, and wherein the method further comprises: providing a second indication using the second indicator to indicate that the remaining capacity satisfies the low capacity threshold.
  • 18. The method of claim 12, further comprising: becoming active responsive to detection of an activation event;performing a self-test subsequent to becoming active; andresponsive to determining that the self-test has been completed successfully, awaiting user input to activate the negative pressure source.
  • 19. The method of claim 18, further comprising: responsive to determining that the self-test has failed, transitioning to an error state and providing a second indication via the at least one visual indicator, the second indication being different than the first indication.
  • 20. The method of claim 12, further comprising storing exudate aspirated from the wound in a canister of the negative pressure wound therapy device.
Priority Claims (1)
Number Date Country Kind
1015656 Sep 2010 GB national
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 17/339,464, filed Jun. 4, 2021, which is a continuation of U.S. patent application Ser. No. 16/141,701, filed on Sep. 25, 2018 and issued as U.S. Pat. No. 11,027,051, which is a continuation of U.S. patent application Ser. No. 15/941,908, filed on Mar. 30, 2018 and issued as U.S. Pat. No. 10,105,473, which is a continuation of U.S. patent application Ser. No. 14/972,734, filed on Dec. 17, 2015 and issued as U.S. Pat. No. 10,058,644, which is a continuation of U.S. patent application Ser. No. 14/256,658, filed on Apr. 18, 2014 and issued as U.S. Pat. No. 9,220,823, which is a continuation of U.S. patent application Ser. No. 13/824,982, filed on Jun. 26, 2013 and issued as U.S. Pat. No. 8,734,425, which is a U.S. National Phase application under 35 U.S.C. § 371 of International Application PCT/GB2011/051745, filed Sep. 16, 2011, which claims priority to Great Britain Patent Application No. 1015656.0, filed Sep. 20, 2010. The disclosures of these prior applications are incorporated by reference in their entireties.

US Referenced Citations (479)
Number Name Date Kind
3572340 Lloyd et al. Mar 1971 A
3787882 Fillmore et al. Jan 1974 A
3972328 Chen Aug 1976 A
4015912 Kofink Apr 1977 A
4062012 Colbert et al. Dec 1977 A
4599052 Langen et al. Jul 1986 A
4643641 Clausen et al. Feb 1987 A
4710165 McNeil et al. Dec 1987 A
4969880 Zamierowski Nov 1990 A
5127388 Cicalese et al. Jul 1992 A
5173033 Adahan Dec 1992 A
5222714 Morinigo et al. Jun 1993 A
5238732 Krishnan Aug 1993 A
5291822 Alsobrooks et al. Mar 1994 A
5349896 Delaney, III et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5360445 Goldowsky Nov 1994 A
5391179 Mezzoli Feb 1995 A
5417743 Dauber May 1995 A
5449003 Sugimura Sep 1995 A
5449347 Preen et al. Sep 1995 A
5449584 Banba et al. Sep 1995 A
5466229 Elson et al. Nov 1995 A
5492313 Pan et al. Feb 1996 A
5549584 Gross Aug 1996 A
5616121 McKay Apr 1997 A
5634391 Eady Jun 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5676525 Berner et al. Oct 1997 A
5685214 Neff et al. Nov 1997 A
5687633 Eady Nov 1997 A
5693013 Geuder Dec 1997 A
5730587 Snyder et al. Mar 1998 A
5743170 Pascual et al. Apr 1998 A
5759570 Arnold Jun 1998 A
5769608 Seale Jun 1998 A
5785508 Bolt Jul 1998 A
5863184 Juterbock et al. Jan 1999 A
5897296 Yamamoto et al. Apr 1999 A
5950523 Reynolds Sep 1999 A
6056519 Morita et al. May 2000 A
6068588 Goldowsky May 2000 A
6071267 Zamierowski Jun 2000 A
6080685 Eady Jun 2000 A
6102680 Fraser et al. Aug 2000 A
6138550 Fingar, Jr. et al. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6145430 Able et al. Nov 2000 A
6158327 Huss Dec 2000 A
6162194 Shipp Dec 2000 A
6174136 Kilayko et al. Jan 2001 B1
6227825 Vay May 2001 B1
6230609 Bender et al. May 2001 B1
6231310 Tojo et al. May 2001 B1
6249198 Clark et al. Jun 2001 B1
6323568 Zabar Nov 2001 B1
6327960 Heimueller et al. Dec 2001 B1
6343539 Du Feb 2002 B1
6413057 Hong et al. Jul 2002 B1
6514047 Burr et al. Feb 2003 B2
6540490 Lilie Apr 2003 B1
6589028 Eckerbom et al. Jul 2003 B1
6604908 Bryant et al. Aug 2003 B1
6618221 Gillis et al. Sep 2003 B2
6623255 Joong et al. Sep 2003 B2
6626891 Ohmstede Sep 2003 B2
6638035 Puff Oct 2003 B1
6652252 Zabar Nov 2003 B2
6655257 Meyer Dec 2003 B1
6673036 Britto Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6756903 Omry et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6815846 Godkin Nov 2004 B2
6823905 Smith et al. Nov 2004 B1
6877419 Ohrle et al. Apr 2005 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7041057 Faupel et al. May 2006 B1
7108683 Zamierowski Sep 2006 B2
7128735 Weston Oct 2006 B2
7151348 Ueda et al. Dec 2006 B1
7361184 Joshi Apr 2008 B2
7363850 Becker Apr 2008 B2
7374409 Kawamura May 2008 B2
7381859 Hunt et al. Jun 2008 B2
7401703 McMichael et al. Jul 2008 B2
7447327 Kitamura et al. Nov 2008 B2
7524315 Blott et al. Apr 2009 B2
7534927 Lockwood et al. May 2009 B2
7550034 Janse Van Rensburg et al. Jun 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7615036 Joshi et al. Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7670323 Hunt et al. Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7722582 Lina et al. May 2010 B2
7758555 Kelch et al. Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7785247 Tatum et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7909805 Weston Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7927319 Lawhorn Apr 2011 B2
7964766 Blott et al. Jun 2011 B2
8007257 Heaton et al. Aug 2011 B2
8025052 Matthews et al. Sep 2011 B2
8034037 Adams et al. Oct 2011 B2
8048046 Hudspeth et al. Nov 2011 B2
8061360 Locke et al. Nov 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8097272 Addison Jan 2012 B2
8105295 Blott et al. Jan 2012 B2
8118794 Weston Feb 2012 B2
8152785 Vitaris Apr 2012 B2
8162907 Heagle Apr 2012 B2
8167869 Wudyka May 2012 B2
8186978 Tinholt et al. May 2012 B2
8188331 Barta et al. May 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8215929 Shen et al. Jul 2012 B2
8235972 Adahan Aug 2012 B2
8241015 Lillie et al. Aug 2012 B2
8241018 Harr Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8257327 Blott et al. Sep 2012 B2
8257328 Augustine et al. Sep 2012 B2
8267918 Johnson et al. Sep 2012 B2
8282611 Weston Oct 2012 B2
8294586 Pidgeon et al. Oct 2012 B2
8303552 Weston Nov 2012 B2
8317774 Adahan Nov 2012 B2
8323264 Weston et al. Dec 2012 B2
8350116 Lockwood et al. Jan 2013 B2
8363881 Godkin Jan 2013 B2
8366690 Locke et al. Feb 2013 B2
8366692 Weston et al. Feb 2013 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8398614 Blott et al. Mar 2013 B2
D679819 Peron Apr 2013 S
D679820 Peron Apr 2013 S
8409157 Haggstrom et al. Apr 2013 B2
8409159 Hu et al. Apr 2013 B2
8409160 Locke et al. Apr 2013 B2
8409170 Locke Apr 2013 B2
8414519 Hudspeth et al. Apr 2013 B2
8425478 Olson Apr 2013 B2
8429778 Receveur et al. Apr 2013 B2
8444612 Patel et al. May 2013 B2
8449267 Pascual et al. May 2013 B2
8449509 Weston May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8500718 Locke et al. Aug 2013 B2
8513481 Gergely et al. Aug 2013 B2
8540688 Eckstein et al. Sep 2013 B2
8545464 Weston Oct 2013 B2
8545466 Andresen et al. Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8579872 Coulthard et al. Nov 2013 B2
8617129 Hartwell Dec 2013 B2
8622981 Hartwell et al. Jan 2014 B2
8628505 Weston Jan 2014 B2
8641691 Fink et al. Feb 2014 B2
8646479 Jaeb et al. Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8708984 Robinson et al. Apr 2014 B2
8715256 Greener May 2014 B2
8734131 McCrone et al. May 2014 B2
8734425 Nicolini May 2014 B2
8764732 Hartwell Jul 2014 B2
8795243 Weston Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8814841 Hartwell Aug 2014 B2
8827983 Braga et al. Sep 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8845603 Middleton et al. Sep 2014 B2
8905985 Allen et al. Dec 2014 B2
8926592 Blott et al. Jan 2015 B2
8945074 Buan et al. Feb 2015 B2
8951235 Allen et al. Feb 2015 B2
8956336 Haggstrom et al. Feb 2015 B2
8974429 Gordon et al. Mar 2015 B2
9012714 Fleischmann Apr 2015 B2
9061095 Adie et al. Jun 2015 B2
9067003 Buan et al. Jun 2015 B2
9084845 Adie et al. Jul 2015 B2
9127665 Locke et al. Sep 2015 B2
9180231 Greener Nov 2015 B2
9199011 Locke et al. Dec 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell Dec 2015 B2
9220823 Nicolini Dec 2015 B2
9314557 Ricci et al. Apr 2016 B2
9408954 Gordon et al. Aug 2016 B2
9421309 Robinson et al. Aug 2016 B2
9446178 Blott et al. Sep 2016 B2
9506463 Locke et al. Nov 2016 B2
9518575 Felber Dec 2016 B2
9629986 Patel et al. Apr 2017 B2
9681993 Wu et al. Jun 2017 B2
9737649 Begin et al. Aug 2017 B2
9877872 Mumby et al. Jan 2018 B2
9956325 Malhi May 2018 B2
10058644 Nicolini Aug 2018 B2
10105473 Nicolini Oct 2018 B2
10143783 Adie et al. Dec 2018 B2
10307517 Allen et al. Jun 2019 B2
20010001278 Drevet May 2001 A1
20010033795 Humpheries Oct 2001 A1
20010043870 Song Nov 2001 A1
20020026946 McKay Mar 2002 A1
20020122732 Oh et al. Sep 2002 A1
20020164255 Burr et al. Nov 2002 A1
20030035743 Lee et al. Feb 2003 A1
20030095879 Oh et al. May 2003 A1
20030099558 Chang May 2003 A1
20030108430 Yoshida et al. Jun 2003 A1
20030110939 Able et al. Jun 2003 A1
20030133812 Puff et al. Jul 2003 A1
20030161735 Kim et al. Aug 2003 A1
20030162071 Yasuda Aug 2003 A1
20030175125 Kwon et al. Sep 2003 A1
20030175135 Heo et al. Sep 2003 A1
20030230191 Ohrle et al. Dec 2003 A1
20040005222 Yoshida et al. Jan 2004 A1
20040021123 Howell et al. Feb 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040066097 Kobayashi et al. Apr 2004 A1
20040071568 Hyeon Apr 2004 A1
20040071572 Greter Apr 2004 A1
20040115076 Lilie et al. Jun 2004 A1
20040118460 Stinson Jun 2004 A1
20040126250 Tsuchiya et al. Jul 2004 A1
20040155741 Godin Aug 2004 A1
20040156730 Lilie et al. Aug 2004 A1
20040163713 Schulze et al. Aug 2004 A1
20040182237 Headley et al. Sep 2004 A1
20040189103 Duncan et al. Sep 2004 A1
20040219059 Barringer et al. Nov 2004 A1
20050031470 Lee Feb 2005 A1
20050098031 Yoon et al. May 2005 A1
20050100450 Bryant et al. May 2005 A1
20050110190 Giardini et al. May 2005 A1
20050111987 Yoo et al. May 2005 A1
20050123422 Lilie Jun 2005 A1
20050124966 Karpowicz et al. Jun 2005 A1
20050129540 Puff Jun 2005 A1
20050135946 Kang et al. Jun 2005 A1
20050142007 Lee et al. Jun 2005 A1
20050142008 Jung et al. Jun 2005 A1
20050155657 Kach et al. Jul 2005 A1
20050163635 Berwanger et al. Jul 2005 A1
20050209560 Boukhny et al. Sep 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050267402 Stewart et al. Dec 2005 A1
20050271526 Chang et al. Dec 2005 A1
20050272142 Horita Dec 2005 A1
20050276706 Radue Dec 2005 A1
20060009744 Erdman et al. Jan 2006 A1
20060017332 Kang et al. Jan 2006 A1
20060018771 Song et al. Jan 2006 A1
20060019144 Hidaka et al. Jan 2006 A1
20060024181 Kim Feb 2006 A1
20060029675 Ginther Feb 2006 A1
20060039806 Becker Feb 2006 A1
20060056979 Yoo et al. Mar 2006 A1
20060056980 Yoo et al. Mar 2006 A1
20060057000 Hyeon Mar 2006 A1
20060061024 Jung et al. Mar 2006 A1
20060073036 Pascual et al. Apr 2006 A1
20060083623 Higgins et al. Apr 2006 A1
20060110259 Puff et al. May 2006 A1
20060118190 Takehana et al. Jun 2006 A1
20060122558 Sherman et al. Jun 2006 A1
20060191575 Naesje Aug 2006 A1
20060192259 Silverbrook Aug 2006 A1
20060210411 Hyeon Sep 2006 A1
20060216165 Lee Sep 2006 A1
20060222532 Lee et al. Oct 2006 A1
20060228224 Hong et al. Oct 2006 A1
20060245947 Seto et al. Nov 2006 A1
20060251523 Lee et al. Nov 2006 A1
20060271020 Huang et al. Nov 2006 A1
20060282174 Haines Dec 2006 A1
20060282175 Haines et al. Dec 2006 A1
20060287632 Sarangapani Dec 2006 A1
20070014837 Johnson et al. Jan 2007 A1
20070016152 Karpowicz et al. Jan 2007 A1
20070032741 Hibner et al. Feb 2007 A1
20070032762 Vogel Feb 2007 A1
20070032763 Vogel Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070041856 Hansen et al. Feb 2007 A1
20070052144 Knirck et al. Mar 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070078444 Larsson Apr 2007 A1
20070091614 Kaisser et al. Apr 2007 A1
20070179460 Adahan Aug 2007 A1
20070196214 Bocchiola Aug 2007 A1
20070219532 Karpowicz et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070256428 Unger et al. Nov 2007 A1
20070260226 Jaeb et al. Nov 2007 A1
20070282283 Kaern et al. Dec 2007 A1
20070292286 Hell et al. Dec 2007 A1
20070295201 Dadd Dec 2007 A1
20080008607 Schade et al. Jan 2008 A1
20080015526 Reiner et al. Jan 2008 A1
20080020178 Ohrle et al. Jan 2008 A1
20080051708 Kumar et al. Feb 2008 A1
20080082040 Kubler et al. Apr 2008 A1
20080089796 Schade et al. Apr 2008 A1
20080094753 Brodkin et al. Apr 2008 A1
20080110336 Cresswell et al. May 2008 A1
20080125697 Gao May 2008 A1
20080125698 Gerg et al. May 2008 A1
20080191399 Chang Aug 2008 A1
20080211435 Imagawa Sep 2008 A1
20080240942 Heinrich et al. Oct 2008 A1
20080260551 Simmons Oct 2008 A1
20080267797 Hell et al. Oct 2008 A1
20080281281 Meyer et al. Nov 2008 A1
20080306456 Riesinger Dec 2008 A1
20080310980 Ramsdorf et al. Dec 2008 A1
20090008306 Cicchello Jan 2009 A1
20090012441 Mulligan Jan 2009 A1
20090028733 Duwel Jan 2009 A1
20090030383 Larsen et al. Jan 2009 A1
20090030402 Adahan Jan 2009 A1
20090053081 Griffiths Feb 2009 A1
20090054855 Blott et al. Feb 2009 A1
20090060750 Chen et al. Mar 2009 A1
20090071551 Chalich Mar 2009 A1
20090081049 Tian et al. Mar 2009 A1
20090087323 Blakey et al. Apr 2009 A1
20090114293 Kanai et al. May 2009 A1
20090123513 Greener May 2009 A1
20090125004 Shen et al. May 2009 A1
20090129955 Schubert May 2009 A1
20090129986 Wimberger-Friedl et al. May 2009 A1
20090148320 Lucas Jun 2009 A1
20090149821 Scherson et al. Jun 2009 A1
20090166411 Kramer et al. Jul 2009 A1
20090169402 Stenberg Jul 2009 A1
20090177051 Arons et al. Jul 2009 A1
20090206778 Roh et al. Aug 2009 A1
20090234306 Vitaris Sep 2009 A1
20090270833 DeBelser et al. Oct 2009 A1
20090299251 Buan Dec 2009 A1
20090299306 Buan Dec 2009 A1
20090304534 Richter Dec 2009 A1
20090312723 Blott et al. Dec 2009 A1
20090312725 Braga Dec 2009 A1
20090315684 Sacco et al. Dec 2009 A1
20100036367 Krohn Feb 2010 A1
20100042059 Pratt et al. Feb 2010 A1
20100068820 Meathrel et al. Mar 2010 A1
20100098566 Kang Apr 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100126484 Skell et al. May 2010 A1
20100145289 Lina et al. Jun 2010 A1
20100160881 Lin et al. Jun 2010 A1
20100191178 Ross et al. Jul 2010 A1
20100211030 Turner et al. Aug 2010 A1
20100244780 Turner et al. Sep 2010 A1
20100249733 Blott et al. Sep 2010 A9
20100265649 Singh et al. Oct 2010 A1
20100268179 Kelch et al. Oct 2010 A1
20100280435 Raney et al. Nov 2010 A1
20100318071 Wudyka Dec 2010 A1
20100320659 Chen et al. Dec 2010 A1
20110000069 Ramsdorf et al. Jan 2011 A1
20110004172 Eckstein et al. Jan 2011 A1
20110015587 Tumey et al. Jan 2011 A1
20110020588 Shimizu et al. Jan 2011 A1
20110028921 Hartwell et al. Feb 2011 A1
20110038741 Lissner et al. Feb 2011 A1
20110043055 Chiang Feb 2011 A1
20110054423 Blott et al. Mar 2011 A1
20110071415 Karwoski et al. Mar 2011 A1
20110077605 Karpowicz Mar 2011 A1
20110081267 McCrone et al. Apr 2011 A1
20110098600 Matsumura et al. Apr 2011 A1
20110103984 Santa May 2011 A1
20110118683 Weston May 2011 A1
20110130712 Topaz Jun 2011 A1
20110144599 Croizat et al. Jun 2011 A1
20110169348 Park Jul 2011 A1
20110171044 Flanigan Jul 2011 A1
20110176945 Drevet Jul 2011 A1
20110176946 Drevet Jul 2011 A1
20110184341 Baker et al. Jul 2011 A1
20110186765 Jaeb et al. Aug 2011 A1
20110196321 Wudyka Aug 2011 A1
20110202220 Seta et al. Aug 2011 A1
20110205646 Sato et al. Aug 2011 A1
20110205647 Osaka et al. Aug 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110229352 Timmer Sep 2011 A1
20110236265 Hasui et al. Sep 2011 A1
20110236277 Lee et al. Sep 2011 A1
20110245682 Robinson et al. Oct 2011 A1
20110251569 Turner et al. Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110311379 Hale et al. Dec 2011 A1
20120000208 Hon et al. Jan 2012 A1
20120008817 Grinker et al. Jan 2012 A1
20120034109 Tout et al. Feb 2012 A1
20120046625 Johannison Feb 2012 A1
20120053543 Miau et al. Mar 2012 A1
20120160091 Dadd et al. Jun 2012 A1
20120165764 Allen et al. Jun 2012 A1
20120177513 Lilie et al. Jul 2012 A1
20120184930 Johannison Jul 2012 A1
20120220960 Ruland Aug 2012 A1
20120232502 Lowing Sep 2012 A1
20120251359 Neelakantan et al. Oct 2012 A1
20120259299 Ryu et al. Oct 2012 A1
20120271256 Locke et al. Oct 2012 A1
20120289895 Tsoukalis Nov 2012 A1
20120289913 Eckstein et al. Nov 2012 A1
20120301341 Ota et al. Nov 2012 A1
20130017110 Villagomez et al. Jan 2013 A1
20130042753 Becker et al. Feb 2013 A1
20130066285 Locke et al. Mar 2013 A1
20130085462 Nip et al. Apr 2013 A1
20130090613 Kelch et al. Apr 2013 A1
20130118622 Patzold et al. May 2013 A1
20130123755 Locke et al. May 2013 A1
20130138054 Fleischmann May 2013 A1
20130144235 Augustine et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130267917 Pan et al. Oct 2013 A1
20130274688 Weston Oct 2013 A1
20130280113 Miranda et al. Oct 2013 A1
20130296762 Toth Nov 2013 A1
20130340870 Ito et al. Dec 2013 A1
20140100516 Hunt et al. Apr 2014 A1
20140114268 Auguste et al. Apr 2014 A1
20140127148 Derain May 2014 A1
20140163490 Locke et al. Jun 2014 A1
20140194835 Ehlert Jul 2014 A1
20140228791 Hartwell Aug 2014 A1
20140276487 Locke et al. Sep 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20150032035 Banwell et al. Jan 2015 A1
20150051560 Askem Feb 2015 A1
20150073363 Kelch et al. Mar 2015 A1
20150217032 Allen et al. Aug 2015 A1
20150335798 De Samber et al. Nov 2015 A1
20160166741 Nicolini Jun 2016 A1
20160319957 Jaeb et al. Nov 2016 A1
20180221547 Nicolini Aug 2018 A1
20190167863 Adie et al. Jun 2019 A1
20190307934 Allen et al. Oct 2019 A1
20200171217 Braga et al. Jun 2020 A9
Foreign Referenced Citations (197)
Number Date Country
101378795 Mar 2009 CN
101385887 Mar 2009 CN
101516431 Aug 2009 CN
101616700 Dec 2009 CN
101676563 Mar 2010 CN
201953601 Aug 2011 CN
103221077 Jul 2013 CN
102005007016 Aug 2006 DE
0208395 Jan 1987 EP
0411564 Feb 1991 EP
0578999 Jan 1994 EP
0604953 Jul 1994 EP
0759521 Feb 1997 EP
0775825 May 1997 EP
0793019 Sep 1997 EP
0809028 Nov 1997 EP
0898076 Feb 1999 EP
0909895 Apr 1999 EP
1114933 Jul 2001 EP
1153218 Nov 2001 EP
0708620 May 2003 EP
0993317 Sep 2003 EP
1406020 Apr 2004 EP
1430588 Jun 2004 EP
1449971 Aug 2004 EP
1554737 Jul 2005 EP
1556942 Jul 2005 EP
1469580 Dec 2005 EP
1757809 Feb 2007 EP
1850005 Oct 2007 EP
1476217 Mar 2008 EP
1460270 Jun 2008 EP
1791579 Jul 2009 EP
2145636 Jan 2010 EP
2161448 Mar 2010 EP
1932481 Jun 2010 EP
2216573 Aug 2010 EP
2253353 Nov 2010 EP
2302127 Mar 2011 EP
1956242 Apr 2011 EP
2366721 Sep 2011 EP
2462908 Jun 2012 EP
2544642 Jan 2015 EP
2648668 Jan 2015 EP
2830555 Feb 2015 EP
2836711 Feb 2015 EP
2254612 Oct 2019 EP
1163907 Oct 1958 FR
1039145 Aug 1966 GB
1220857 Jan 1971 GB
2235877 Mar 1991 GB
2273133 Jun 1994 GB
2306580 May 1997 GB
2342584 Apr 2000 GB
2418738 Apr 2006 GB
2433298 Jun 2007 GB
2000105011 Apr 2000 JP
2000220570 Aug 2000 JP
2000300662 Oct 2000 JP
2001241382 Sep 2001 JP
2001286807 Oct 2001 JP
2006233925 Sep 2006 JP
2008183244 Aug 2008 JP
2008194294 Aug 2008 JP
2010185458 Aug 2010 JP
2013514871 May 2013 JP
WO-8707683 Dec 1987 WO
WO-9421312 Sep 1994 WO
WO-9819068 May 1998 WO
WO-0000743 Jan 2000 WO
WO-0007653 Feb 2000 WO
WO-0021586 Apr 2000 WO
WO-0022298 Apr 2000 WO
WO-0049968 Aug 2000 WO
WO-0056378 Sep 2000 WO
WO-0061206 Oct 2000 WO
WO-0079154 Dec 2000 WO
WO-0116488 Mar 2001 WO
WO-0179693 Oct 2001 WO
WO-02087058 Oct 2002 WO
WO-02090772 Nov 2002 WO
WO-03057307 Jul 2003 WO
WO-03085810 Oct 2003 WO
WO-03099356 Dec 2003 WO
WO-03101508 Dec 2003 WO
WO-2004007960 Jan 2004 WO
WO-2004081421 Sep 2004 WO
WO-2005001287 Jan 2005 WO
WO-2005009488 Feb 2005 WO
WO-2005123170 Dec 2005 WO
WO-2006046060 May 2006 WO
WO-2006052839 May 2006 WO
WO-2006058801 Jun 2006 WO
WO-2006059098 Jun 2006 WO
WO-2006062276 Jun 2006 WO
WO-2006069875 Jul 2006 WO
WO-2006069884 Jul 2006 WO
WO-2006069885 Jul 2006 WO
WO-2006092333 Sep 2006 WO
WO-2006111775 Oct 2006 WO
WO-2006117207 Nov 2006 WO
WO-2006122268 Nov 2006 WO
WO-2007019038 Feb 2007 WO
WO-2007049876 May 2007 WO
WO-2007055642 May 2007 WO
WO-2007067359 Jun 2007 WO
WO-2007087810 Aug 2007 WO
WO-2007087811 Aug 2007 WO
WO-2007092397 Aug 2007 WO
WO-2007113597 Oct 2007 WO
WO-2008013896 Jan 2008 WO
WO-2008027449 Mar 2008 WO
WO-2008031418 Mar 2008 WO
WO-2008039223 Apr 2008 WO
WO-2008039314 Apr 2008 WO
WO-2008048481 Apr 2008 WO
WO-2008049029 Apr 2008 WO
WO-2008100440 Aug 2008 WO
WO-2008110022 Sep 2008 WO
WO-2008135997 Nov 2008 WO
WO-2008154158 Dec 2008 WO
WO-2009004367 Jan 2009 WO
WO-2009019415 Feb 2009 WO
WO-2009047524 Apr 2009 WO
WO-2009066104 May 2009 WO
WO-2009066105 May 2009 WO
WO-2009071924 Jun 2009 WO
WO-2009089390 Jul 2009 WO
WO-2009095170 Aug 2009 WO
WO-2009103031 Aug 2009 WO
WO-2009124100 Oct 2009 WO
WO-2009124125 Oct 2009 WO
WO-2009126103 Oct 2009 WO
WO-2009146441 Dec 2009 WO
WO-2009151645 Dec 2009 WO
WO-2009156984 Dec 2009 WO
WO-2009158128 Dec 2009 WO
WO-2010017484 Feb 2010 WO
WO-2010021783 Feb 2010 WO
WO-2010033574 Mar 2010 WO
WO-2010033613 Mar 2010 WO
WO-2010033769 Mar 2010 WO
WO-2010039481 Apr 2010 WO
WO-2010051068 May 2010 WO
WO-2010051418 May 2010 WO
WO-2010056977 May 2010 WO
WO-2010093753 Aug 2010 WO
WO-2010126444 Nov 2010 WO
WO-2010142959 Dec 2010 WO
WO-2010144089 Dec 2010 WO
WO-2010147533 Dec 2010 WO
WO-2011003163 Jan 2011 WO
WO-2011068310 Jun 2011 WO
WO-2011082461 Jul 2011 WO
WO-2011087871 Jul 2011 WO
WO-2011097361 Aug 2011 WO
WO-2011097362 Aug 2011 WO
WO-2011103890 Sep 2011 WO
WO-2011115851 Sep 2011 WO
WO-2011130542 Oct 2011 WO
WO-2011130549 Oct 2011 WO
WO-2011135285 Nov 2011 WO
WO-2011135286 Nov 2011 WO
WO-2011135287 Nov 2011 WO
WO-2011144888 Nov 2011 WO
WO-2011146535 Nov 2011 WO
WO-2011148188 Dec 2011 WO
WO-2011150529 Dec 2011 WO
WO-2012028842 Mar 2012 WO
WO-2012034238 Mar 2012 WO
WO-2012038724 Mar 2012 WO
WO-2012048179 Apr 2012 WO
WO-2012088572 Jul 2012 WO
WO-2012095245 Jul 2012 WO
WO-2012131237 Oct 2012 WO
WO-2012140180 Oct 2012 WO
WO-2012140378 Oct 2012 WO
WO-2012142002 Oct 2012 WO
WO-2012143665 Oct 2012 WO
WO-2013006932 Jan 2013 WO
WO-2013007973 Jan 2013 WO
WO-2013010907 Jan 2013 WO
WO-2013015827 Jan 2013 WO
WO-2013019017 Feb 2013 WO
WO-2013064852 May 2013 WO
WO-2013083800 Jun 2013 WO
WO-2013136181 Sep 2013 WO
WO-2013149078 Oct 2013 WO
WO-2014008348 Jan 2014 WO
WO-2014016759 Jan 2014 WO
WO-2014020440 Feb 2014 WO
WO-2014020443 Feb 2014 WO
WO-2014022440 Feb 2014 WO
WO-2014108476 Jul 2014 WO
WO-2014113253 Jul 2014 WO
WO-2015022334 Feb 2015 WO
WO-2015022340 Feb 2015 WO
Non-Patent Literature Citations (92)
Entry
Annex to the Communication, the Opposition of European Patent No. 2773383, dated Sep. 13, 2019, 17 pages.
Appeal Decision for Japanese Patent Application No. 2013528768, dated Jul. 14, 2017, 20 pages.
Brief Communication—Letter from the opponent of the Patent, re the Opposition for European Patent No. 3146986, dated Feb. 3, 2022, 2 pages.
Brief Communication—Letter from the opponent of the Patent, re the Opposition for European Patent No. 3146986, dated Jan. 26, 2022, 4 pages.
Brief Communication—Letter from the Opponent, re the Opposition of European Patent No. 2773383, dated Mar. 24, 2021, 4 pages.
Brief Communication—Letter from the Opponent, re the Opposition of European Patent No. 3326656, dated Oct. 14, 2021, 41 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for European Patent No. 3146986, dated Dec. 15, 2021, 7 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition for Simmons & Simmons for European Patent No. 3146986, dated Feb. 7, 2022, 2 pages.
Brief Communication—Letter from the Proprietor of the Patent, re the Opposition of European Patent No. 2773383, dated Mar. 24, 2021, 25 pages.
Brief Communication of the Opposition Proceedings for European Patent No. 3326656, dated Aug. 25, 2021, 34 pages.
Brief Communication of the Opposition Proceedings for European Patent No. 3326656, dated Jul. 14, 2022, 11 pages.
British Standards Institution, “Sterilization of medical devices and packaging,” retrieved from URL: https://shop.bsigroup.com/en/Browse-By-Subject/Medical-Device-Standards/Sterilization-of-medical-devices-and-packaging/ onMar. 12, 2020, 1 page.
Communication of further notices of opposition pursuant to Rule 79(2) EPC for the European Patent No. 3146986, dated Aug. 20, 2020, 2 pages.
Consolidated List of Cited Opposition Documents of the European Patent No. 2773383, dated Jan. 23, 2020, 1 page.
Decision by a different Opposition Division for European Application No. 11802142.7, dated Sep. 24, 2021, 22 pages.
Decision by Opposition Division re the Opposition of European Patent No. 2773383, revoking a patent with claims essentially corresponding to the claims presented in the new requests dated Sep. 24, 2021, 22 pages.
Decision of Rejection dated Apr. 4, 2016 for Japanese Application No. 2013-528768, 9 pages.
Decision revoking the European Patent (Art. 101 (3)(b) EPC) for European Patent No. 2773383, dated Sep. 24, 2021, 56 pages.
Dempsey D.J., “Sterilization of Medical Devices: A Review,” Journal of Biomaterials Applications, Jan. 1989, vol. 3, pp. 454-523.
Diels K., et al., “Leybold Vacuum Handbook,”Pergamon Press, 1966, 10 pages.
European Extended Search Report and Office Action dated Feb. 14, 2017 for European Application No. 16193508.5.
Extent of the Opposition and Request for European Patent No. 3326656, dated Feb. 12, 2021, 58 pages.
Hoxey E., “Sterilization—Regulatory Requirements and Supporting Standards,” BSI National Standards Body, Medical Device White Paper Series, Publication Date Unknown, 27 pages.
Information about the result of oral proceedings for European Patent No. 2773383, dated May 19, 2021, 2 pages.
Interlocutory Decision in Opposition and Accompanying Items for European Patent No. 3146986, dated Feb. 23, 2022, 28 pages.
International Preliminary Report on Patentability for Application No. PCT/GB2011/051745, dated Mar. 26, 2013, 7 pages.
International Search Report and Written Opinion for Application No. PCT/IB2011/002943, dated Jan. 28, 2013, 24 pages.
International Search Report for Application No. PCT/GB2011/051745, dated Feb. 2, 2012, 5 pages.
KCI, Inc., “Acti V.A.C. Therapy System,” User Manual, Sep. 2007, 64 pages.
KCI Licensing Inc, “Prevena™ Incision Management System,” Clinician Guide, Instructions for Use, 390061 Rev C, Nov. 2009, 12 pages.<gdiv class=“ginger-extension-definitionpopup” style=“left: 525.701px; top: 16.8889px; z-index: 2147483646; display: none;”><gdiv class=“ginger-dp”> <gdiv class=“ginger-dp-content”> <gdiv class=“ginger-dp-title”><gspan id=“dp-title”>January</gspan></gdiv> <gdiv class=“ginger-dp-description” id=“dp-description”>the first month of the year; begins 10 days after the winter solstice</gdiv> <gdiv class=“ginger-dp-more”>More <gspan>(Definitions, Synonyms, Translation)</gspan><gdiv>.</gdiv></gdiv><gdiv>.
KCI Licensing, Inc., “V.A.C.Via™—Negative Pressure Wound Therapy System,” 7-Day V.A.C.® Therapy System, Instructions for Use, 360063 Rev B, Aug. 2010, 24 pages.
KCI to Launch the V.A.C.VIA™, an Advanced Mobile Healing Technology, dated Apr. 26, 2010, 3 pages.
KCI USA Inc., “SNAP™ Therapy System,” Instructions for Use, SNAP™ Therapy Cartridge, Jul. 2016, 2 pages.
Kendall ULTEC Hydrocolloid Dressing (4x4“),” Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page.
Kinetic Concepts, Inc. Q2 2010 Earnings Call Transcript, dated Jul. 27, 2010, 25 pages.
Kinetic Concepts Inc., V.A.C. Therapy, dated Jan. 11, 2011, 2 pages.
Letter of the Opponent for the European Patent No. 2773383, dated Jun. 15, 2022, 57 pages.
Letter relating to the Appeal Procedure for the Opposition of the European Patent No. 2618860, dated Dec. 23, 2019, 5 pages.
Maintenance of the patent with the documents specified in the final decision, re the opposition of European patent No. EP3146986, mailed on Jun. 7, 2022, 1 page.
Martin L.H., et al., “A Manual of Vacuum Practice,” Melbourne University Press, first published 1947, reprinted 1948, 12 pages.
Matsunaga K., et al., “Gas Permeability of Thermoplastic Polyurethane Elastomers,” Polymer Journal, Jun. 2005, vol. 37, No. 6, pp. 413-417.
Morcos A.C., “Voice Coil Actuators & Their Use in Advanced Motion Control Systems,” Motion, Jul./Aug. 1995, pp. 25-27.
“SNAP™—Wound Care System,” Instructions for Use (L20897), Dec. 9, 2007, 16 pages.
Notice of Communication of amended entries concerning the representative (R. 143(1 )(h) EPC) and enclosed letter from the proprietor of the patent dated Jan. 8, 2021 for the European Patent No. 3146986, dated Jan. 20, 2021, 6 pages.
Notice of Opposition—Statement of Facts and Arguments for the European Patent No. 2618860, dated Aug. 26, 2016, 9 pages.
Notice of Opposition—Statement of Facts and Evidence for the European Patent No. 2773383, dated Dec. 28, 2018, 20 pages.
Notice of Opposition to a European Patent No. 2618860, dated Mar. 16, 2016, 5 pages.
Notice of Reasons for Rejection for Japanese Patent Application No. 2016153604, dated Jul. 3, 2017, 4 pages.
Observations filed by Third Party for the European Patent No. 2773383, dated Jan. 28, 2020, 7 pages.
Office Action and Search Report dated Sep. 1, 2015 for Chinese Application No. 201180055731.0, 14 pages.
Office Action dated Jul. 19, 2016 for Chinese Application No. 201180055731.0, 11 pages.
Office Action dated Jul. 27, 2015, for Japanese Application No. 2013-528768.
Office Action dated Apr. 28, 2017 for Canadian Application No. 2811718, 3 pages.
Opponent Arguments for the European Patent No. EP2773383, dated Jan. 28, 2020, 25 pages.
Opponent's Statement of Facts and Arguments for the European Patent No. 3146986, dated Jul. 30, 2020, 6 pages.
Opponent Submissions Prior to Oral Proceedings for Opposition to European Patent No. 2618860, dated Sep. 14, 2017, 4 pages.
Opponent's Written Submission in Preparation for the Oral Proceedings, opposition of the European Patent No. 2773383, dated Mar. 16, 2020, 8 pages.
Opponent's Written Submission in Preparation for the Oral Proceedings, the Opposition of European Patent No. 3146986, dated Dec. 7, 2021, 1 page.
Opposition—Statement of Facts and Evidence for Opposition for the European Patent No. 2618860, filed on Mar. 16, 2016, 9 pages.
Opposition by KCI Licensing Inc. to EP2708216 Smith & Nephew Inc., Submitted as Evidence in Support of tile Appeal re European Patent No. 2618860, dated Apr. 5, 2018, 5 pages.
Oral Proceeding Minutes, Decision Rejecting the Opposition, and Grounds of Decision, re European Patent No. EP2618860, dated Jan. 19, 2018, 11 pages.
Park S.M., et al., “Design and Analysis of VCA for Fuel Pump in Automobile,” World of Academy of Science, Engineering and Technology, vol. 80, 2011, pp. 573-576.
Patentee Final Written Submissions in Advance of Oral Proceedings for Opposition to European Patent No. 2618860, dated Sep. 13, 2017, 4 pages.
Preliminary Opinion of the Opposition Division for the European Patent No. 2618860, dated Dec. 22, 2016, 5 pages.
Proprietor Arguments for the European Patent No. EP2773383, dated Jan. 28, 2020, 32 pages.
Proprietor Reply to Statement of Opponent's Grounds of Appeal, re European Patent No. 2618860, dated Sep. 28, 2018, 38 pages.
Proprietor's Written Submission in Preparation for the Oral Proceedings, opposition of European Patent No. 2773383, dated Mar. 18, 2020, 9 pages.
Proprietor's Written Submission in the Opposition Proceedings for European Patent No. 3326656, dated Jul. 13, 2022, 65 pages.
Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation).
Rangwala A.S., “Reciprocating Machinery Dynamics,” New Age International Publishers, ISBN:81-224-1813-9, 2006, 6 pages.
Reply of the Patent Proprietor to the Notice of the Opposition, the Opposition of European Patent No. 2773383, dated Jun. 3, 2019, 11 pages.
Smith & Nephew, “Smith & Nephew Introduces the First, Pocket-sized, Canister Free, Portable Negative Wound Therapy System in the EU,” Cision PR Newswire press release, May 25, 2011, 4 pages.
Smith & Nephew, “Smith & Nephew Introduces the First, Pocket-sized, Canister Free, Portable Negative Wound Therapy System in the EU,” Press Release, May 25, 2011, 3 pages.
Smith & Nephew, “Patient Home Care Information,” PICO booklet, Mar. 2011, 12 pages.
Smith & Nephew, “PICO—The Early Studies,” Case Study booklet, Mar. 2011, 24 pages.
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System,” Spiral Booklet, Jul. 2011, 11 pages.<gdiv class=“ginger-extension-definitionpopup” style=“left: 405.424px; top: 16.8889px; z-index: 2147483646; display: none;”xgdiv class=“ginger-dp”> <gdiv class=“ginger-dp-content”> <gdiv class=“ginger-dp-title”><gspan id=“dp-title”>March</gspan></gdiv> <gdiv class=“ginger-dp-description” id=“dp-description”>the act of marching; walking with regular steps (especially in a procession of some kind)</gdiv> <gdiv class=“ginger-dp-more”>More <gspan>(Definitions, Synonyms, Translation)</gspan></gdiv>.</gdiv></gdiv></gdiv>.
Smith & Nephew, “Pictures of Pump Assembly of Device Obtained for the application No. 170203441.5,” Oct. 28, 2020, 28 pages.
Snap™ Therapy System, “Monograph,” KCI, 3 pages.
Statement of Grounds of Appeal filed by proprietor for European patent No. 2773383, mailed on Feb. 2, 2022, 53 pages.
Statement of Opponent's Grounds of Appeal for European Patent No. EP2618860, dated May 18, 2018, 4 pages.
Summons to Attend Oral Proceedings pursuant to Rule 115(1) for European Patent No. 3326656, mailed on Dec. 16, 2021, 17 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC for European Patent No. 2773383, mailed on Sep. 30, 2020, 19 pages.
Summons to attend oral proceedings pursuant to Rule 115(1) EPC for the European Patent No. 3146986, mailed on Apr. 19, 2021, 10 pages.
Summons to Attend Oral Proceedings pursuant to rule 115(1) EPC for Application No. 11802142.7, mailed on Jun. 3, 2020, 20 pages.
The Constructor, “Reciprocating Pump—Components, Working and Uses,” Retrieved from https://theconstructor.org/practical-guide/reciprocating-pumpcomponents-working-uses/2914/, on Jan. 21, 2020, 4 pages.
Trademark/Service Mark Statement of Use (15 U.S.C. Section 1051(d)) for V.A.C.VIA, dated Sep. 22, 2010, 6 pages.
U.S. Office Action dated Aug. 15, 2013 for U.S. Appl. No. 13/824,982, 14 pages.
Wikipedia, “Pump,” retrieved from https://en.wikipedia.org/wiki/Pump on Mar. 13, 2020, 11 pages.
Written Submission by the Opponent for Opposition of European Patent No. EP2773383, dated Jul. 22, 2020, 2 pages.
Written Submission by the Proprietor for Opposition of European Patent No. EP2773383, dated Jul. 22, 2020, 15 pages.
Communication pursuant to Rule 82(2) EPC for Application No. 16193508.5, dated Jun. 14, 2022, 4 pages.
Termination of the Opposition Proceedings with Maintenance of European Patent No. 3146986, dated Jul. 8, 2022, 1 page.
Related Publications (1)
Number Date Country
20220273861 A1 Sep 2022 US
Continuations (6)
Number Date Country
Parent 17339464 Jun 2021 US
Child 17747874 US
Parent 16141701 Sep 2018 US
Child 17339464 US
Parent 15941908 Mar 2018 US
Child 16141701 US
Parent 14972734 Dec 2015 US
Child 15941908 US
Parent 14256658 Apr 2014 US
Child 14972734 US
Parent 13824982 US
Child 14256658 US